RAPID MIGRAINE RELIEF WITH ALGINATE-BASED THIN FILM

Project Information

RAPID

Grant agreement ID: 829615

DOI

10.3030/829615

Project closed

EC signature date 25 October 2018

Start date 1 November 2018

End date 30 June 2021

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 2 902 248,75

EU contribution

€ 2 031 574,13

Coordinated by

KLARIA AB
Sweden

Periodic Reporting for period 3 - RAPID (RAPID MIGRAINE RELIEF WITH ALGINATE-BASED THIN FILM)

Reporting period: 2020-11-01 to 2021-06-30

Summary of the context and overall objectives of the project

The RAPID project aims to improve the lives of migraine patients. We know that migraine patients suffer not only from common acute co-morbities such as anxiety and depression, but also longer-term elevated risk of certain neurodegenerative diseases if their migraine attacks are not effectively managed. The RAPID project aims to develop a rapid-acting migraine treatment that also gives the migraine patient confidence in a consistent effect every time they use it. This confidence, in turn, will not only lower the risk of developing anxiety in relation to whether their treatment will work or not, but also allow them to return to their normal lives more quickly after a migraine attack. An additional benefit of the RAPID project is that the resulting product is very compact, easily fitting into a wallet or mobile phone case, so that a patient will always have their medication with them. This results in an earlier intervention in their migraine attack - a key factor in effective acute and chronic migraine management.

The overall objectives of the project are to manufacture and test the final product and assemble a registration package suitable for submission to regulatory authorities for marketing authorization in the EU and US.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The RAPID project has established a robust and realistic clinical trial design and assembled all of the documentation necessary for ethical approval of the pivotal clinical trial. In addition, the manufacturing site and contract has been established and several small-scale feasibility trial have been performed in preparation for the final full-scale manufacturing. In addition, the project has now submitted patent applications in all relevant markets, including the EU and US in order to ensure commercial success of the final product.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The RAPID project has one goal: To register a migraine treatment that will help patients intervene in their migraine attack earlier and more reliably than previously possible. Early and reliable intervention is key to both acute and chronic health of patients and to their overall quality of life.

klaria-logo-rgb.jpg